AXIN2 Genotype

Most inherited colon cancer risk is chased through the usual suspect genes, and a normal result there feels reassuring. But a small number of families carry a different faulty gene that leaves a clue in an unexpected place: the mouth. If you or close relatives are missing several adult teeth and there is colon cancer or polyps in the family tree, this is a result worth knowing.

This test reads whether you carry a rare inherited change in the AXIN2 (axis inhibition protein 2) gene that can meaningfully affect your risk. It is a once-in-a-lifetime answer, and for the small group who carry a damaging variant, it can reshape how early and how often you get screened for colon cancer.

What AXIN2 Does in Your Body

AXIN2 is a gene, not a substance floating in your blood. It carries the instructions for a scaffold protein that acts as a brake on a core growth signal your cells use during development and tissue renewal, a signal scientists call Wnt/beta-catenin. When that signal needs to turn off, AXIN2 helps assemble the machinery that clears the signal away.

This brake matters most in two places. In developing teeth, the Wnt signal shapes how many teeth form, so a faulty brake can leave teeth missing. In the lining of the colon, the same signal drives constant cell turnover, and a weakened brake can let cells grow into polyps and, over time, cancer. That shared biology is why one gene ties together two very different-looking problems.

Tooth Agenesis: The Earliest Clue

The most consistent finding tied to damaging AXIN2 variants is congenitally missing adult teeth, known as tooth agenesis or, when many are missing, oligodontia. The pattern can be recognizable: the second premolars are among the teeth most commonly absent, though many AXIN2 carriers are missing a large number of teeth spread throughout the mouth. Variants that truncate the protein and cut it short tend to produce more severe and more syndromic dental features than milder single-letter (missense) changes.

In a Saudi study of orthodontic patients, carrying two copies of one common variant (rs2240308) was linked to hypodontia, missing teeth, with roughly three times the odds (odds ratio 2.893). The dental clue often shows up decades before any colon problem. In one review of reported carriers, people who had only tooth agenesis averaged 22.5 years of age, while those with colon cancer or polyps averaged 53.3 years.

What this means for you: if you have several missing adult teeth and a family history of colon cancer, that combination is exactly the pattern where checking this gene can pay off, because the mouth may be flagging a risk that will not surface in the colon for years.

Colorectal Polyps and Cancer

For people who carry a truly damaging AXIN2 variant, the colon risk appears substantial. In a French cohort of 3,322 people evaluated for suspected inherited colon cancer, damaging loss-of-function variants raised the odds of colorectal cancer predisposition roughly 12-fold (odds ratio 11.89, 95% CI 5.103 to 28.93). Even so, national guidelines still rate the overall evidence for AXIN2 as limited and note there is not yet enough data to pin down a precise lifetime cancer risk.

Among the carriers in that cohort, the findings clustered clearly. About 91% of those who had a colonoscopy showed adenomatous polyposis (multiple precancerous polyps), and 40% had a colorectal or other digestive cancer. At least 60% also had multiple missing teeth, reinforcing the dental-cancer overlap. Reassuringly for the general public, these variants are rare: only 0.24% of that referred cohort carried a pathogenic or likely pathogenic change.

What this means for you: a positive result here is uncommon, but when it appears it is a strong signal, not a maybe. It moves you into a hereditary-risk category where earlier and more frequent colonoscopy becomes the point of testing at all. In carriers, specialists typically start high-quality colonoscopy around age 25 to 30 and repeat it every 2 to 3 years, or more often if polyps are found.

The Mixed Story on Common Variants

Not every AXIN2 change carries the same weight. Common single-letter variants such as rs2240308 have been studied for broader cancer risk with genuinely conflicting results. A Japanese study found one genotype was linked to lower lung cancer risk (about 69% lower, odds ratio 0.31, 95% CI 0.12 to 0.79), and one pooled analysis agreed that a given allele carried roughly 18% lower overall risk. Another meta-analysis, rating its own evidence as only moderate, reported the opposite direction.

This looks contradictory only if you expect one gene to have one fixed effect. It is more useful to separate two categories. Rare, damaging loss-of-function variants that break the gene carry a strong, consistent risk for polyps and colon cancer. Common polymorphisms are weak risk modifiers whose direction shifts by population, cancer type, and study, and they are not a reliable basis for personal risk prediction. The signal that matters for a preventive decision is the rare pathogenic variant, not the common one.

A One-Time Test You Act On for Years

Your genotype does not change over your lifetime, so there is no trend to track and no reason to repeat this specific test. The value is not in retesting; it is in integrating one result into your medical decisions over decades. Get it once, from a saliva or blood sample, and the answer stays valid.

The tracking that does matter is the phenotype the gene points to. If you carry a damaging variant, the ongoing monitoring shifts to colonoscopy on a hereditary-risk schedule set by a specialist, not to rechecking the gene. In that sense the gene is the map, and colon surveillance is the route you actually walk.

What an AXIN2 Finding Should Make You Do Next

A pathogenic result is not the end of a workup, it is the start of one. The most useful next steps are less about a single number and more about combining findings and involving the right people.

• Confirm the finding: an unexpected variant flagged on a broad panel or a consumer-style report should be verified by a clinical-grade method before you act on it.
• Order the companion evaluation: a positive result should prompt colonoscopy and referral to gastroenterology, since polyposis was present in the large majority of carriers who were scoped.
• Loop in genetics: a genetic counselor can interpret whether your specific variant is truly damaging versus uncertain, and can map who else in the family should test.
• Watch for the pattern, not one clue alone: missing adult teeth plus a family history of early colon cancer or polyposis is the combination that most warrants action.

One related test worth knowing about is tumor-tissue AXIN2 methylation, studied to predict recurrence in colon cancer that has already been diagnosed. That is a different measurement in a different setting and does not tell you about your inherited risk, so do not confuse it with this germline genotype.

When a Genetic Result Can Mislead You

Genetic tests fool people in specific ways, and knowing them keeps you from over- or under-reacting to a result.

• A negative result is not a full clearance: the assay only looks for the variants it is designed to detect, so a negative does not rule out every rare change in the gene, nor does a normal standard cancer panel mean this gene was even checked.
• Carrying a variant is not a verdict: the gene shows incomplete, age-dependent expression, so some carriers have cancer without missing teeth, some have missing teeth without documented cancer, and younger carriers can look dental-only simply because colon risk rises with age.
• Common variants are not clinical predictors: the widely studied polymorphisms carry small and inconsistent effects and should not be read as a personal cancer risk score.
• Consumer reports differ from clinical testing: a variant seen in a direct-to-consumer genomics file may not be confirmed or clinically interpreted, and warrants clinical-grade retesting before any decision.